Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024(Status and Outlook)

Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024(Status and Outlook)



Report Overview:

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

The Global Drugs for Vulvovaginal Candidiasis Market Size was estimated at USD 831.60 million in 2023 and is projected to reach USD 909.31 million by 2029, exhibiting a CAGR of 1.50% during the forecast period.

This report provides a deep insight into the global Drugs for Vulvovaginal Candidiasis market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Vulvovaginal Candidiasis Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Vulvovaginal Candidiasis market in any manner.

Global Drugs for Vulvovaginal Candidiasis Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bayer

Perrigo

J & J

Pfizer

Bristol-Myers Squibb

Effik

Teva

Sanofi

Cisen Pharmaceutical

Kingyork Group

Market Segmentation (by Type)

Cream

Pessary

Other

Market Segmentation (by Application)

Hospital & Clinic

Pharmacy

Geographic Segmentation
  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Drugs for Vulvovaginal Candidiasis Market
  • Overview of the regional outlook of the Drugs for Vulvovaginal Candidiasis Market:
Key Reasons to Buy this Report:
  • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
  • This enables you to anticipate market changes to remain ahead of your competitors
  • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
  • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
  • Provision of market value (USD Billion) data for each segment and sub-segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • 6-month post-sales analyst support
Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Vulvovaginal Candidiasis Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Vulvovaginal Candidiasis
1.2 Key Market Segments
1.2.1 Drugs for Vulvovaginal Candidiasis Segment by Type
1.2.2 Drugs for Vulvovaginal Candidiasis Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Drugs for Vulvovaginal Candidiasis Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Drugs for Vulvovaginal Candidiasis Market Competitive Landscape
3.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2019-2024)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturers (2019-2024)
3.3 Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Drugs for Vulvovaginal Candidiasis Sales Sites, Area Served, Product Type
3.6 Drugs for Vulvovaginal Candidiasis Market Competitive Situation and Trends
3.6.1 Drugs for Vulvovaginal Candidiasis Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
4.1 Drugs for Vulvovaginal Candidiasis Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Drugs for Vulvovaginal Candidiasis Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Drugs for Vulvovaginal Candidiasis Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2019-2024)
6.3 Global Drugs for Vulvovaginal Candidiasis Market Size Market Share by Type (2019-2024)
6.4 Global Drugs for Vulvovaginal Candidiasis Price by Type (2019-2024)
7 Drugs for Vulvovaginal Candidiasis Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Vulvovaginal Candidiasis Market Sales by Application (2019-2024)
7.3 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) by Application (2019-2024)
7.4 Global Drugs for Vulvovaginal Candidiasis Sales Growth Rate by Application (2019-2024)
8 Drugs for Vulvovaginal Candidiasis Market Segmentation by Region
8.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region
8.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region
8.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Vulvovaginal Candidiasis Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Bayer
9.1.1 Bayer Drugs for Vulvovaginal Candidiasis Basic Information
9.1.2 Bayer Drugs for Vulvovaginal Candidiasis Product Overview
9.1.3 Bayer Drugs for Vulvovaginal Candidiasis Product Market Performance
9.1.4 Bayer Business Overview
9.1.5 Bayer Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.1.6 Bayer Recent Developments
9.2 Perrigo
9.2.1 Perrigo Drugs for Vulvovaginal Candidiasis Basic Information
9.2.2 Perrigo Drugs for Vulvovaginal Candidiasis Product Overview
9.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Product Market Performance
9.2.4 Perrigo Business Overview
9.2.5 Perrigo Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.2.6 Perrigo Recent Developments
9.3 J and J
9.3.1 J and J Drugs for Vulvovaginal Candidiasis Basic Information
9.3.2 J and J Drugs for Vulvovaginal Candidiasis Product Overview
9.3.3 J and J Drugs for Vulvovaginal Candidiasis Product Market Performance
9.3.4 J and J Drugs for Vulvovaginal Candidiasis SWOT Analysis
9.3.5 J and J Business Overview
9.3.6 J and J Recent Developments
9.4 Pfizer
9.4.1 Pfizer Drugs for Vulvovaginal Candidiasis Basic Information
9.4.2 Pfizer Drugs for Vulvovaginal Candidiasis Product Overview
9.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Product Market Performance
9.4.4 Pfizer Business Overview
9.4.5 Pfizer Recent Developments
9.5 Bristol-Myers Squibb
9.5.1 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Basic Information
9.5.2 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Overview
9.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Market Performance
9.5.4 Bristol-Myers Squibb Business Overview
9.5.5 Bristol-Myers Squibb Recent Developments
9.6 Effik
9.6.1 Effik Drugs for Vulvovaginal Candidiasis Basic Information
9.6.2 Effik Drugs for Vulvovaginal Candidiasis Product Overview
9.6.3 Effik Drugs for Vulvovaginal Candidiasis Product Market Performance
9.6.4 Effik Business Overview
9.6.5 Effik Recent Developments
9.7 Teva
9.7.1 Teva Drugs for Vulvovaginal Candidiasis Basic Information
9.7.2 Teva Drugs for Vulvovaginal Candidiasis Product Overview
9.7.3 Teva Drugs for Vulvovaginal Candidiasis Product Market Performance
9.7.4 Teva Business Overview
9.7.5 Teva Recent Developments
9.8 Sanofi
9.8.1 Sanofi Drugs for Vulvovaginal Candidiasis Basic Information
9.8.2 Sanofi Drugs for Vulvovaginal Candidiasis Product Overview
9.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Product Market Performance
9.8.4 Sanofi Business Overview
9.8.5 Sanofi Recent Developments
9.9 Cisen Pharmaceutical
9.9.1 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Basic Information
9.9.2 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Overview
9.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Market Performance
9.9.4 Cisen Pharmaceutical Business Overview
9.9.5 Cisen Pharmaceutical Recent Developments
9.10 Kingyork Group
9.10.1 Kingyork Group Drugs for Vulvovaginal Candidiasis Basic Information
9.10.2 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Overview
9.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Market Performance
9.10.4 Kingyork Group Business Overview
9.10.5 Kingyork Group Recent Developments
10 Drugs for Vulvovaginal Candidiasis Market Forecast by Region
10.1 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast
10.2 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country
10.2.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size Forecast by Region
10.2.4 South America Drugs for Vulvovaginal Candidiasis Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Vulvovaginal Candidiasis by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Drugs for Vulvovaginal Candidiasis by Type (2025-2030)
11.1.2 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Drugs for Vulvovaginal Candidiasis by Type (2025-2030)
11.2 Global Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2025-2030)
11.2.1 Global Drugs for Vulvovaginal Candidiasis Sales (Kilotons) Forecast by Application
11.2.2 Global Drugs for Vulvovaginal Candidiasis Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings